Nymox Pharmaceuticals Gets $15M Financing Deal

HASBROUCK HEIGHTS, N.J.--Drug developer Nymox Pharmaceutical
Corp. said Thursday it has obtained a commitment for $15 million in
equity financing from institutional investors.

The money will be used for general corporate purposes. The
financing also will help the company continue with research into
new drugs including one called NX-1207, which may treat an enlarged
prostate.

The investors may get common stock at a 3 percent discount to
the market price, the company said. The timing and amount of each
placement is in the sole discretion of the company. There are no
warrants, price resets, and no restrictions on other corporate
financing.

Products currently marketed by Nymox include tests for measuring
tobacco product exposure sold under the NicAlert and TobacAlert
names and a test to aid in the diagnosis of Alzheimer’s
disease.